Clinical Trial Update: Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. [Phase 2]

View source ↗

Summary

A Phase 2 study completed evaluating two doses of GlaxoSmithKline's live attenuated human rotavirus vaccine in healthy infants, comparing two formulations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 2 | Status: COMPLETED